论文部分内容阅读
目的 探讨外科手术切除与瘤床间质内缓释化疗对复发性脑胶质瘤的治疗效果.方法 回顾性分析2014年6月至2016年6月于瑞金医院神经外科就诊的114例复发性脑胶质瘤患者,根据治疗方法不同,将患者分为两组,其中外科手术切除联合瘤床间质内缓释化疗组(A组)51例,仅外科手术切除组(B组)63例.手术后2～3周所有患者均接受放疗.统计分析两组之间的Karnofsky行为表现量表评分、肿瘤复发率和生存时间的差异.结果 两组患者的术前一般资料比较差异无统计学意义,术后的Karnofsky行为表现量表评分[70(60～80)vs.70(60～80)]差异也无统计学意义(P＞ 0.05).A组患者的顺铂缓释聚合物在术后1个月完全生物降解.A组患者脑胶质瘤在术后6个月的复发率与B组相比(16/51=31.4％vs.25/63=39.7％)差异无统计学意义(P＞ 0.05),但在12个月和24个月的复发率分别为45.1％(23/51)、62.7％(32/51),均显著低于B组患者12个月(37/63=58.7％)和24个月(51/63=81.0％)的复发率(P ＜0.05).A组患者总体生存时间的中位数(427.5 d)明显长于B组患者(211.0 d),差异有统计学意义(P=0.001).结论 用顺铂缓释聚合物进行瘤床间质内化疗能降低复发性脑胶质瘤患者外科手术切除后的肿瘤复发率,并延长患者的生存时间.“,”Objective To explore the efficacy of surgical resection and continuous infusion with intratumoral chemotherapy on recurrent cerrebral glioma. Methods A total of 114 eligible patients with recurrent glioma were selected according to the inclusion and exclusion criteria.Among them, 51 patients with surgical resection combined with interstitial sustained release chemotherapy (group A) and 63 patients with surgical resection alone (group B). All these patients received radiation therapy for 2 to 3 weeks after surgery. The difference in Karnofsky performance scale scores, recurrence rate and survival time between these two groups was statistically analyzed. Results There was no significant difference in preoperative general condition between these two groups. There was no significant difference in post-operative Karnofsky performance scale scores between these two groups [70 (60 ～ 80) vs. 70 (60 ～ 80) ] (P＞ 0. 05). The complete biodegradation of the carrier system in group A occurred one month after surgery. The recurrence rate of glioma in group A was not significantly different from that of group B in 6 months after surgery (16/51 = 31. 4％ vs. 25/63 = 39. 7％) (P＞ 0. 05), but the recurrence rates in 12 months and 24 months were 45. 1％ (23/51) and 62. 7％ (32/51) respectively, which were significantly lower than those of group B in 12 months (37/63 = 58. 7％) and 24 months of group A was 427. 5 d, it was significantly longer than the median survival period (211. 0 d) of patients in group B (P = 0. 001). Conclusion The continuous infusion of intratumoral chemotherapy with slow release polymer cisplatin can reduce the recurrence rate of tumor and prolong the survival period of patients with recurrent cerebral glioma.